Phibro Animal Health Corporation (PAHC) - NASDAQ
  • Yesterday, 4:37 PM
    • Phibro Animal (NASDAQ:PAHC) declares $0.10/share quarterly dividend, in line with previous.
    • Forward yield 1.96%
    • Payable Sept. 28; for shareholders of record Sept. 7; ex-div Sept. 2.
    | Yesterday, 4:37 PM
  • Mon, May 9, 4:48 PM
    • Phibro Animal (NASDAQ:PAHC) declares $0.10/share quarterly dividend, in line with previous.
    • Forward yield 1.91%
    • Payable June 22; for shareholders of record June 1; ex-div May 27.
    | Mon, May 9, 4:48 PM | 1 Comment
  • Mon, May 9, 4:26 PM
    • Phibro Animal (NASDAQ:PAHC): FQ3 EPS of $0.38 misses by $0.05.
    • Revenue of $183.5M (-2.1% Y/Y) misses by $13.74M.
    • Press Release
    | Mon, May 9, 4:26 PM | 1 Comment
  • Mon, Apr. 11, 12:47 PM
    | Mon, Apr. 11, 12:47 PM
  • Fri, Apr. 8, 6:01 PM
    • In a statement, Phibro Animal Health (NASDAQ:PAHC) says it will request a hearing with the FDA to address the safety of Mecadox (carbadox), its antibiotic that's been sold to U.S. pork producers for more than 40 years to control swine dysentery and bacterial swine enteritis (a diarrheal disease that strikes young pigs). It has also been used to promote weight gain and feed efficiency.
    • The company takes issue with the agency's plan to rescind approval of the drug due to concerns that it leaves trace amounts of a cancer-causing residue that could present a risk to humans. Its specific concern is that the agency did not reach out to the company before its announcement, despite knowing that that safety studies sponsored by Phibro are due to be completed in 90 days. The company is confident that the studies will confirm the safety of the product.
    • In a press release issued earlier today, the FDA cited the July 2014 findings by the Codex Alimentarius Commission that there is no safe level of residues of carbadox or its metabolites in food that represents an acceptable risk to humans. It goes on to say, though, that people need not make changes to their food choices since the cancer risk is based on an assumed lifetime of consuming pork liver (undoubtedly a small group) or other pork products containing carbadox residues.
    • Phibro doesn't disclose specific Mecadox sales, but it is a member of its "MFA and other" business segment, which generated $336M in sales last year which represented over 71% of the company's top-line of $471M. About half of MFA's revenues are to the poultry industry, with swine, cattle, dairy and other customers accounting for the remainder. The bulk of MFA's sales are antibacterials, a line of 13 products according to the 10-K. Mecadox is sold primarily in the U.S.
    | Fri, Apr. 8, 6:01 PM
  • Tue, Feb. 9, 4:38 PM
    • Phibro Animal (NASDAQ:PAHC): FQ2 EPS of $0.39 misses by $0.02.
    • Revenue of $192M (+1.7% Y/Y) misses by $6.27M.
    • Press Release
    | Tue, Feb. 9, 4:38 PM
  • Mon, Feb. 8, 4:38 PM
    • Phibro Animal (NASDAQ:PAHC) declares $0.10/share quarterly dividend, in line with previous.
    • Forward yield 1.17%
    • Payable March 23; for shareholders of record March 2; ex-div Feb. 29.
    | Mon, Feb. 8, 4:38 PM
  • Wed, Jan. 13, 7:02 AM
    • Phibro Animal Health (NASDAQ:PAHC) acquires privately held MVP Laboratories for an undisclosed sum. The Omaha, Nebraska-based firm develops, manufactures and sells livestock vaccines, vaccine adjuvants and other products, including the MJPRRS autogenous swine vaccine, which Phibro exclusively distributes pursuant to its agreement with MJ Biologics.
    • The company will discuss the transaction during its investor conference call on February 10.
    | Wed, Jan. 13, 7:02 AM
  • Nov. 9, 2015, 5:13 PM
    • Phibro Animal (NASDAQ:PAHC): FQ1 EPS of $0.44 beats by $0.03.
    • Revenue of $187.1M (-0.2% Y/Y) misses by $5.18M.
    | Nov. 9, 2015, 5:13 PM
  • Nov. 9, 2015, 4:51 PM
    • Phibro Animal (NASDAQ:PAHC) declares $0.10/share quarterly dividend, in line with previous.
    • Forward yield 1.21%
    • Payable Dec. 23; for shareholders of record Dec. 2; ex-div Nov. 30.
    | Nov. 9, 2015, 4:51 PM
  • Sep. 10, 2015, 7:29 AM
    • Phibro Animal Health Corp. (PAHC -3.1%) FQ4 results: Revenues: $185M (+0.7%); Gross Profit: $60.8M (+12.0%); SG&A: $39.9M (-3.2%); Operating Income: $21M (+60.3%); Net Income: $10.4M (+159.1%); EPS: $0.26 (+155.3%).
    • FY2015 results: Revenues: $748.6M (+8.2%); Gross Profit: $236.4M (+13.8%); SG&A: $148.7M (+3.3%); Operating Income: $87.7M (+37.5%); Net Income: $60.3M (+999%); EPS: $1.51 (+999%).
    • Fiscal 2016 Guidance: Revenues: $780M - 800M; non-GAAP EBITDA: $113M - 117M; non-GAAP EPS: $1.65 - 1.75.
    | Sep. 10, 2015, 7:29 AM
  • Sep. 9, 2015, 5:54 PM
    • Phibro Animal (NASDAQ:PAHC): FQ4 EPS of $0.44 beats by $0.06.
    • Revenue of $185M (+0.7% Y/Y) misses by $3.51M.
    | Sep. 9, 2015, 5:54 PM
  • Jul. 27, 2015, 4:34 PM
    • Phibro Animal (NASDAQ:PAHC) declares $0.10/share quarterly dividend, in line with previous.
    • Forward yield 1.09%
    • Payable Sept. 23; for shareholders of record Sept. 2; ex-div Aug. 31.
    | Jul. 27, 2015, 4:34 PM
  • May 11, 2015, 5:19 PM
    • Phibro Animal (NASDAQ:PAHC): FQ3 EPS of $0.41 beats by $0.05.
    • Revenue of $187M (+7.9% Y/Y) misses by $0.76M.
    | May 11, 2015, 5:19 PM
  • May 11, 2015, 4:50 PM
    • Phibro Animal (NASDAQ:PAHC) declares $0.10/share quarterly dividend, in line with previous.
    • Forward yield 1.18%
    • Payable June 24; for shareholders of record June 3; ex-div June 1.
    | May 11, 2015, 4:50 PM
  • Apr. 21, 2015, 9:42 AM
    • Bristol-Myers Squibb (BMY +1.3%) upgraded to Overweight with $80 (21% upside) by Morgan Stanley.
    • Align Technology (ALGN +4.6%) upgraded to Overweight with a $79 (46% upside) price target by Morgan Stanley.
    • Biocryst Pharmaceuticals (BCRX +4.5%) upgraded to Neutral with $12 (20% upside) by Bank of America.
    • Rosetta Genomics (ROSG -1%) upgraded to Buy with $5.50 (32% upside) price target by Cantor Fitzgerald.
    • Phibro Animal Health (PAHC -2.7%) downgraded to Underweight with $35 (3% upside) price target by Morgan Stanley.
    • Impax Laboratories (IPXL +0.5%) downgraded to Sell with $36 (28% downside risk) price target by UBS.
    | Apr. 21, 2015, 9:42 AM
Company Description
Phibro Animal Health Corp. is a developer, manufacturer and marketer of a broad range of animal health and mineral nutrition products for use in the production of poultry, swine, cattle, dairy and aquaculture. The company operates through three business segment: Animal Health, Mineral Nutrition... More
Sector: Healthcare
Industry: Specialized Health Services
Country: United States